Clinical Trial Results:
Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, parallel-group and multicentre clinical phase III study investigating the effects on NT-proBNP over 6 months.
Summary
|
|
EudraCT number |
2007-003070-26 |
Trial protocol |
DE |
Global completion date |
02 Dec 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Jun 2016
|
First version publication date |
18 Jun 2016
|
Other versions |
|
Summary report(s) |
Results Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.